Author:
Meng Zilu,Zheng Hanxue,Liu Yang,Guo Xiaojia,Chu Songlin,Zhou Wen,Li Yanhong,Bai Jun,Zhang Liansheng,Li Lijuan
Funder
Supported by the National Natural Science Foundation of China
Commissioned by the National Clinical Medical Research Center for Hematological Diseases
Construction of clinical medical research center of Gansu Science and Technology project
Gansu Province science and technology project natural science foundation
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Pui CH, Mullighan CG, Evans WE, Relling MV (2012) Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 120:1165–1174
2. Schrappe M, Reiter A, Zimmermann M et al (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster Leukemia 14:2205–2222
3. Möricke A, Reiter A, Zimmermann M et al (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:4477–4489
4. Stanulla M, Cavé H, Moorman AV (2020) IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood 135:252–260
5. Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373:1541–1552